Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Supplemental Figure S6: XTX301 induced cell signature and pathway analysis: single-sample Gene Set Enrichment Analysis (ssGSEA) was performed for all samples and for selected gene sets of interest (see figure 5e). Each ssGSEA score summarizes the overall expression level of genes involved in a certain biological process of interest in a biological sample. For each gene set, ssGSEA scores were analyzed with respect to treatment groups and significant differences compared to the vehicle group were determined by Wilcoxon rank sum test. Boxplots showing ssGSEA scores (y-axis) of all samples for gene sets of interest. Each point is a sample. Samples were grouped by treatment group (x-axis). Colors indicate different treatment groups. * (Wilcoxon test, p< 0.05) ** (Wilcoxon test, p<0.01).